<DOC>
	<DOC>NCT02305446</DOC>
	<brief_summary>The purpose of this trial is to assess the safety of a Meningococcal Group B Vaccine and to collect blood donation. Sera panel obtained from blood donations will be used as a control to measure the immunoresponse to the Meningococcal Group B Vaccine in other studies.</brief_summary>
	<brief_title>Safety and Blood Donations in Adults Vaccinated With rMenB+OMV NZ.</brief_title>
	<detailed_description />
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningitis, Meningococcal</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1. Individuals of 18 through 50 years of age on the day of informed consent; 2. Individuals who had voluntarily given written informed consent after the nature of the study had been explained according to local regulatory requirements, prior to study entry; 3. Individuals who could comply with study procedures including followup; 4. Males, females of nonchildbearing potential or females of childbearing potential who are using an effective birth control method. 1. Progressive, unstable or uncontrolled clinical conditions; 2. Hypersensitivity, including allergy, to any component of vaccines or medical equipment whose use is foreseen in this study; 3. Abnormal function of the immune system; 4. Chronic clinical significant conditions; 4. Been administered any group B meningococcal vaccine at any time prior to informed consent; 5. Current or previous, confirmed or suspected disease caused by N.meningitidis.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>